Mark Groper News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

An Ottawa-based startup working on treatments that use the body’s immune system to target cancer, COVID-19 and other diseases has landed millions of dollars in financing to ratchet up its research efforts. Orion Biotechnology’s new series-A round worth US$11.5 million is being led by Keiretsu Forum, a global syndicate of angel investors headquartered in San Francisco.  The new funding will help the firm expand its clinical trials of drug candidates produced by its proprietary platform that targets G-protein coupled receptors, or GPCRs, which play a key role in diseases such as cancer, HI...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. PHASE 1 TEST RESULTS FOR A NOVEL HIV PREVENTION GEL PRESENTED AT THE HIVR4P MEETING Orion Biotechnology Canada Ltd.January 28, 2021 GMT Ottawa, Canada, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that they will be presenting the results of their Phase 1 study of OB-002H at the HIVR4P virtual meeting ( https://www.hivr4p.org/ ). The OB-002H-101 Phase 1 study was ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ORION BIOTECHNOLOGY PROJECT AWARDED GRANT TO ADVANCE DRUG DISCOVERY Orion Biotechnology Canada Ltd.January 14, 2021 GMT Genève SWITZERLAND, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that its drug discovery project was awarded funding of CHF 0.9M from Innosuisse, the Swiss Innovation Agency. The project will allow Orion, in collaboration with the University of Geneva, to fur...